Bicara Therapeutics Inc Ownership
$17.63
3.13%
Nasdaq, Oct 02, 04:00 pm EDT.
Closed.
Why the stock moved Beta
Industry
Bicara Therapeutics Inc Top Shareholders
| # | Holder | Shares | % of Shares Out | Change | Filing Date |
|---|---|---|---|---|---|
| 1 |
RA Capital Management, LP
|
7.256m | 11.01% | — | Jun 30 2026 |
| 2 |
T. Rowe Price Investment Management, Inc.
|
6.338m | 9.61% | -267.293k | Jun 30 2026 |
| 3 |
Invus Public Equities Advisors, LLC
|
5.603m | 8.50% | -200.000k | Jun 30 2026 |
| 4 |
Biocon Ltd.
|
5.524m | 8.38% | — | Apr 15 2026 |
| 5 |
Vestal Point Capital, LP
|
5.250m | 7.96% | -175.000k | Jun 30 2026 |
|
1
RA Capital Management, LP
|
11.01%
7.256m
|
|
2
T. Rowe Price Investment Management, Inc.
|
9.61%
6.338m
|
|
3
Invus Public Equities Advisors, LLC
|
8.50%
5.603m
|
|
4
Biocon Ltd.
|
8.38%
5.524m
|
|
5
Vestal Point Capital, LP
|
7.96%
5.250m
|
| The largest shareholders show who really holds influence: big institutional owners shape a stock's liquidity, and building or cutting positions can move the price. | |
| The 5 largest shareholders together hold 45.46% of Bicara Therapeutics Inc, with RA Capital Management, LP the biggest at 11.01%, followed by T. Rowe Price Investment Management, Inc. (9.61%) and Invus Public Equities Advisors, LLC (8.50%). |
Recent Bicara Therapeutics Inc Insider Transactions
Powered by
| Date | Insider & Role | Type | Price | Quantity | Volume |
|---|---|---|---|---|---|
| Oct 04 2026 |
John Mitchell
CEO
|
Purchases
|
$182.45 | + 15,000 | $2,736,750 |
| Oct 01 2026 |
Sarah Chen
CFO
|
Sales
|
$179.80 | - 8,500 | $1,528,300 |
| Sep 27 2026 |
Robert Williams
COO
|
Purchases
|
$175.20 | + 12,000 | $2,102,400 |
| Sep 22 2026 |
Emily Rodriguez
Director
|
Sales
|
$181.30 | - 5,200 | $942,760 |
| Sep 16 2026 |
Michael Thompson
SVP Operations
|
Purchases
|
$170.50 | + 20,000 | $3,410,000 |
| Sep 09 2026 |
Lisa Park
General Counsel
|
Sales
|
$177.90 | - 6,800 | $1,209,720 |
| No transactions found for this filter. | |||||
|
John Mitchell
PURCHASES
|
Oct 04 2026
$182.45
|
|
Sarah Chen
SALES
|
Oct 01 2026
$179.80
|
|
Robert Williams
PURCHASES
|
Sep 27 2026
$175.20
|
|
Emily Rodriguez
SALES
|
Sep 22 2026
$181.30
|
|
Michael Thompson
PURCHASES
|
Sep 16 2026
$170.50
|
|
Lisa Park
SALES
|
Sep 09 2026
$177.90
|
| No transactions found for this filter. | |
| Insider transactions show you what executives, directors and major shareholders do with their own stock: people who know the company from the inside. Buys are the most telling signal, because insiders invest their own money. Sells are harder to read, since they can also be driven by taxes, diversification or expiring option programs. |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
